Treatment of early stage Hodgkin's disease.
Current trends in the treatment of patients with Stages I and II Hodgkin's disease are discussed in this review. Recommendations for staging procedures and the updated staging classification are described. Long-term results with extended field radiation therapy overall and in subgroups of patients are detailed. As follow-up and numbers of patients treated with extended field radiation therapy have accrued, prognostic factors, predictive of outcome, have emerged. The evolution of combined modality treatment with chemotherapy and radiation therapy and, more recently, chemotherapy alone for early stage patients is reviewed. Discussion is made of recent programs in various centers to reduce toxicity while maintaining good results. Long-term potential toxicities are described, and recommendations are made for long-term follow-up monitoring.
Straus
D J
DJ
Department of Medicine, Memorial Sloan-Kettering Cancer Center, New York, NY 10021.
D000293:Adolescent; D000328:Adult; D000367:Age Factors; D000368:Aged; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000009:adverse effects / Q000627:therapeutic use; D001799:Blood Sedimentation; D002986:Clinical Trials as Topic; D003131:Combined Modality Therapy; D005260:Female; D005500:Follow-Up Studies; D006689:Hodgkin Disease / Q000473:pathology / Q000628:therapy*; D006801:Humans; D007813:Laparotomy; D008297:Male; D008875:Middle Aged; D009367:Neoplasm Staging; D009381:Neoplasms, Radiation-Induced / Q000209:etiology; D016609:Neoplasms, Second Primary / Q000209:etiology; D011379:Prognosis; D011878:Radiotherapy / Q000009:adverse effects / Q000379:methods; D013156:Splenectomy; D016019:Survival Analysis